01
What changed in pharmaceuticals regulation and policy this week?
Government decisions, new rules and policy shifts reported this week.
02
On August 14, 2026, the US FDA office leadership overruled its internal clinical review team to grant approval for Replimune's drug Tudriqev.
Read at citeline.com ↗03
Capricor Therapeutics received authorization from the FDA to file an amendment to its approval application for a Duchenne muscular dystrophy cell therapy.
Read at fiercebiotech.com ↗04
The European Medicines Agency (EMA) has officially accepted the marketing authorization application for VLA15, a Lyme disease vaccine candidate developed by Pfizer and Valneva.
Read at citeline.com ↗05
On August 14, 2026, the US Food and Drug Administration (FDA) introduced a new risk-based framework for assessing drug product packaging.
Read at citeline.com ↗06
Government funding initiatives for biotechnology hubs are expanding across regions including Pennsylvania and Kansas City as of August 2026.
Read at biopharmadive.com ↗07
The UK Medicines and Healthcare products Regulatory Agency (MHRA) approved the drug vimseltinib (brand name Romvizma) on August 14, 2026.
Read at gov.uk ↗What funding rounds and acquisitions happened in pharmaceuticals this week?
The week’s notable investments, financing rounds, acquisitions and strategic deals.
08
Skye Bioscience and Redx Pharma have entered into an agreement to merge their operations to form a new public company named Fibrx Therapeutics.
Read at fiercebiotech.com ↗What products launched in pharmaceuticals this week?
Notable product launches, releases and platform updates from the week.
09
Health startup Amble is selling a $345 'Oh Sh*t Bag' containing potassium iodide, prussian blue, and ondansetron for use in radiological emergencies.
Read at futurism.com ↗10
Bristol Myers Squibb (BMS) received regulatory approval for Zenbexus on August 14, 2026.
Read at citeline.com ↗11
The US Food and Drug Administration (FDA) granted accelerated approval to Zenbexus (iberdomide) in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adult patients with relapsed or refractory multiple myeloma.
Read at pharmexec.com ↗12
On August 14, 2026, the newly public biotechnology company Yarrow announced a first-in-class therapeutic approach targeting Graves' disease and Thyroid Eye Disease (TED).
Read at citeline.com ↗13
The FDA granted accelerated approval to Bristol Myers Squibb's drug Zenbexus (iberdomide) for the treatment of adults with relapsed or refractory multiple myeloma.
Read at medcitynews.com ↗What financial results were reported in pharmaceuticals this week?
Earnings, guidance and other financial results reported this week.
14
WuXi AppTec Co. has seen its stock price rally by 100% despite being designated as a Chinese military company by the Pentagon.
Read at bloomberg.com ↗15
Vogenx, a biotechnology company based in Raleigh, North Carolina, raised $81 million in its initial public offering on the Nasdaq exchange.
Read at medcitynews.com ↗What research was published in pharmaceuticals this week?
New research findings and studies published this week.
16
Researchers at the Universitair Medisch Centrum Groningen (UMCG) in the Netherlands found that low-dose digoxin reduces heart-failure hospitalizations by 25%.
Read at sciencedaily.com ↗17
Researchers at the Whitehead Institute, led by Ankur Jain, Whitney Henry, and Pushkal Sharma, discovered that polyamines act as storage molecules for iron to prevent cellular damage.
Read at genengnews.com ↗What partnerships were announced in pharmaceuticals this week?
Partnerships, integrations and joint projects announced this week.
18
The Pharmaceutical Care Management Association (PCMA) announced on August 13, 2026, that nine major pharmacy benefit managers (PBMs) in the United States have agreed to integrate TrumpRx pricing information into their real-time benefit tools.
Read at fiercehealthcare.com ↗What people moved in and out of pharmaceuticals roles this week?
Executive appointments and departures reported this week.
19
Ying Huang, the former CEO of Legend Biotech, has been appointed as the new leader of K2 Therapeutics.
Read at fiercebiotech.com ↗20
BioNTech has appointed Guido Oelkers as its new CEO to lead the company's strategic shift toward oncology.
Read at pharmavoice.com ↗What else happened in pharmaceuticals this week?
Developments from the week that fit none of the other sections.
21
BioCryst Pharmaceuticals CEO Charlie Gayer announced that the company is discontinuing its internal drug discovery efforts.
Read at fiercebiotech.com ↗22
Tony Hickson, Chief Business Officer of Cancer Research Horizons, discusses the organization's mission to develop new childhood cancer treatments through the C-Further initiative.
Read at labiotech.eu ↗23
The pharmaceutical and biotechnology sectors are seeing over $16 billion in capital investments across the United States, including major projects by AstraZeneca, Merck, and Eli Lilly in Virginia and Pennsylvania.
Read at genengnews.com ↗24
MedAdvisor Solutions has officially rebranded to Adheris, effective August 14, 2026.
Read at pharmexec.com ↗25
MapLight Therapeutics is prioritizing its phase 3-ready schizophrenia drug following mixed clinical trial results reported in July 2026.
Read at fiercebiotech.com ↗26
Bristol Myers Squibb announced the selection of Houston, Texas, for a new $2.3 billion multi-modal manufacturing campus.
Read at genengnews.com ↗6 of 8 other developments events are listed; the rest were ranked lower by importance and multi-source corroboration and are not shown.